Sopharma AD (WSE:SPH)

Poland flag Poland · Delayed Price · Currency is PLN
7.96
-0.54 (-6.35%)
Apr 28, 2026, 2:27 PM CET
78.88%
Market Cap 3.86B
Revenue (ttm) 5.68B
Net Income (ttm) 288.18M
Shares Out n/a
EPS (ttm) 0.84
PE Ratio 13.40
Forward PE n/a
Dividend 0.36 (4.27%)
Ex-Dividend Date Dec 18, 2025
Volume 352
Average Volume 614
Open 8.90
Previous Close 8.50
Day's Range 7.94 - 8.90
52-Week Range 4.00 - 16.00
Beta 0.11
RSI 53.72
Earnings Date Apr 30, 2026

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana to reduce the stress; and medical devices... [Read more]

Sector Healthcare
Founded 1933
Employees 5,932
Stock Exchange Warsaw Stock Exchange
Ticker Symbol SPH
Full Company Profile

Financial Performance

In 2025, Sopharma AD's revenue was 2.63 billion, an increase of 22.57% compared to the previous year's 2.15 billion. Earnings were 133.52 million, an increase of 74.97%.

Financial numbers in BGN

News

There is no news available yet.